Esbe - Pharma SRL
Esbe - Pharma reported total assets of 808,162 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Jul 2026).
The score of Esbe - Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +65 % Total assets +51 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Esbe - Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 113,949 € | ||||
| Equity | 739,799 € | ||||
| Cash | 601,816 € | ||||
| EBITDA | 184,888 € | ||||
| Total assets | 808,162 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Jul 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 14 Jun 2024
- Year ended 31 Dec 2022filed on 25 Aug 2023
- Year ended 31 Dec 2021filed on 30 Jun 2022
Esbe - Pharma's financial analysis
- Solvency91.5%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Esbe - Pharma
Esbe - Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0430.045.342
- VAT number
- BE0430045342
- Peppol
- Registered · 0208:0430045342 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 11 Dec 1986
- Registered office
- 6200 Châtelet
- Latest accounts
- 2025 · filed on 31 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Esbe - Pharma (SRL) has been based in Châtelet since 1986, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 113,949 € and equity of 739,799 €; its revenue is not published. Its solvency stands at 91.5%, above the median of its sector (41.5%).
Companies similar to Esbe - Pharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Hopland Retail sale of pharmaceutical products Meise · balance sheet 809,017 €
- Pharmacie Fivez Retail sale of pharmaceutical products Dalhem · balance sheet 809,540 €
- Geassocieerde Apotheek Dhondt Retail sale of pharmaceutical products Gavere · balance sheet 806,404 €
- AllGor Retail sale of pharmaceutical products Kortrijk · balance sheet 810,045 €
- Wijmenput Retail sale of pharmaceutical products Aalst · balance sheet 805,856 €
- Idealpharma Retail sale of pharmaceutical products Antwerp · balance sheet 804,498 €
- Zoniapharma Retail sale of pharmaceutical products Sint-Genesius-Rode · balance sheet 804,389 €
- Cobra Apotheek Dessel Retail sale of pharmaceutical products Dessel · balance sheet 813,901 €
Frequently asked questions about Esbe - Pharma
What is the revenue of Esbe - Pharma?
Esbe - Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Esbe - Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0430045342 for Esbe - Pharma, if the company is VAT-registered. Its company number (CBE) is 0430.045.342.
Where is the registered office of Esbe - Pharma?
According to the CBE register, the registered office of Esbe - Pharma is in 6200 Châtelet.
What is the equity of Esbe - Pharma?
At the close of the 2025 financial year, the equity of Esbe - Pharma amounts to 739,799 €, a solvency of 91.5% of total assets.
Who manages Esbe - Pharma?
The register lists 1 active mandates at Esbe - Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Esbe - Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →